XKRX115450
Market cap570mUSD
Dec 26, Last price
11,560.00KRW
1D
7.84%
1Q
20.29%
Jan 2017
-30.57%
IPO
190.45%
Name
HLB Therapeutics Co Ltd
Chart & Performance
P/E
—
P/S
15.47
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
7.70%
Rev. gr., 5y
4.28%
Revenues
53.75b
+26.76%
Net income
-2.30b
L-79.72%
CFO
3.33b
P
Earnings
Mar 17, 2025
Profile
HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrical and electronic components, such as motors, pumps, and transformers. The company was formerly known as G-treeBNT Co., Ltd. and changed its name to HLB Therapeutics Co.,Ltd. in December 2021. HLB Therapeutics Co.,Ltd. was founded in 2000 and is headquartered in Seongnam, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 53,749,063 26.76% | 42,402,742 -2.72% | 43,586,411 1.53% | |||||
Cost of revenue | 57,284,369 | 45,206,850 | 53,547,201 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (3,535,306) | (2,804,108) | (9,960,790) | |||||
NOPBT Margin | ||||||||
Operating Taxes | (730) | (2,102,964) | (146,636) | |||||
Tax Rate | ||||||||
NOPAT | (3,535,306) | (701,145) | (9,814,154) | |||||
Net income | (2,302,158) -79.72% | (11,353,689) -33.98% | (17,197,218) 1.74% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 12,947,506 | (7,079) | 40,000,054 | |||||
BB yield | -4.12% | 0.00% | -10.36% | |||||
| Debt | ||||||||
Debt current | 8,059,960 | 51,946,235 | 50,805,773 | |||||
Long-term debt | 2,708,822 | 184,737 | 641,400 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | 522,938 | 851,984 | 2,634,396 | |||||
Net debt | (78,105,041) | (30,089,989) | (52,834,840) | |||||
| Cash flow | ||||||||
Cash from operating activities | 3,326,877 | (8,808,556) | (11,267,898) | |||||
CAPEX | (5,759,592) | (5,587,543) | (3,933,143) | |||||
Cash from investing activities | (20,159,921) | (41,930,362) | 14,352,559 | |||||
Cash from financing activities | (5,280,908) | (3,317,883) | 82,854,193 | |||||
FCF | 13,621,685 | (11,371,119) | (13,353,294) | |||||
| Balance | ||||||||
Cash | 31,309,022 | 61,885,533 | 100,567,446 | |||||
Long term investments | 57,564,801 | 20,335,428 | 3,714,567 | |||||
Excess cash | 86,186,370 | 80,100,824 | 102,102,692 | |||||
Stockholders' equity | 46,826,727 | 35,834,836 | (56,206,191) | |||||
Invested Capital | 135,237,422 | 145,126,929 | 240,006,377 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 71,664 | 129,604 | 58,454 | |||||
Price | 4,385.00 -18.96% | 5,410.63 -18.08% | 6,604.59 -51.54% | |||||
Market cap | 314,245,386 -55.19% | 701,241,284 81.64% | 386,065,045 -48.03% | |||||
EV | 247,193,190 | 682,559,308 | 344,590,489 | |||||
EBITDA | 4,944,020 | (1,138,459) | (8,260,256) | |||||
EV/EBITDA | 50.00 | |||||||
Interest | 1,113,300 | 5,146,352 | 1,160,426 | |||||
Interest/NOPBT | ||||||||